Brian P. Ziemba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian P. Ziemba has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Joseph J. Falke
University of Colorado at Boulder
10 shared publications - Douglas R. Seals
University of Colorado Boulder
4 shared publications - Glenn Robert Masson
Division of Cancer Research, School of Medicine, Ninewells Hospital
3 shared publications James J. Richey
From the Department of Integrative Physiology, University of Colorado Boulder (V.E.B., R.A.G.-R., A.G.C., N.S.V., B.P.Z., Z.J.S., J.J.R., M.C.Z., D.R.S.)
3 shared publications- David N. M. Jones
Department of Pharmacology, University of Colorado School of Medicine, Aurora, USA
2 shared publications Dov B. Ballak
Department of Integrative Physiology, University of Colorado Boulder, Boulder, USA
2 shared publications
Latest Publications
- 27 May 2022
- Published by Springer Nature in GeroScience
- Vol. 45 (1) , 65-84
Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs
Aging is characterized by declines in physiological function that increase risk of age-associated diseases and limit healthspan, mediated in part by chronic low-grade inflammation. Interleukin (IL)-37 suppresses inflammation in pathophysiological states but has not been studied in the context of aging in otherwise healthy humans. Thus, we investigated associations between IL-37 and markers of healthspan in 271 young (18–39 years; n = 41), middle-aged (40–64 years; n = 162), and older (65 + years; n = 68) adults free of overt clinical disease. After conducting a thorough validation of AdipoGen’s IL-37 ELISA, we found that plasma IL-37 is lower in older adults (young: 339 ± 240, middle-aged: 345 ± 234; older: 258 ± 175 pg/mL; P = 0.048), despite elevations in pro-inflammatory markers. As such, the ratios of circulating IL-37 to pro-inflammatory markers were considerably lower in older adults (e.g., IL-37 to C-reactive protein: young, 888 ± 918 vs. older, 337 ± 293; P = 0.02), indicating impaired IL-37 responsiveness to a pro-inflammatory state with aging and consistent with the notion of immunosenescence. These ratios were related to multiple indicators of healthspan, including positively to cardiorespiratory fitness (P < 0.01) and negatively to markers of adiposity, blood pressure, and blood glucose (all P < 0.05). Lastly, we correlated single-nucleotide polymorphisms (SNPs) in the IL37 and ILR8 (the co-receptor for IL-37) genes and found that variants in IL37 SNPs tended to be associated with blood pressure and adiposity (P = 0.08–0.09) but did not explain inter-individual variability in circulating IL-37 concentrations across age (P ≥ 0.23). Overall, our findings provide novel insights into a possible role of IL-37 in biological aging in humans.
- 27 May 2022
- Published by Springer Nature in GeroScience
- Vol. 45 (1) , 65-84
Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs
Aging is characterized by declines in physiological function that increase risk of age-associated diseases and limit healthspan, mediated in part by chronic low-grade inflammation. Interleukin (IL)-37 suppresses inflammation in pathophysiological states but has not been studied in the context of aging in otherwise healthy humans. Thus, we investigated associations between IL-37 and markers of healthspan in 271 young (18–39 years; n = 41), middle-aged (40–64 years; n = 162), and older (65 + years; n = 68) adults free of overt clinical disease. After conducting a thorough validation of AdipoGen’s IL-37 ELISA, we found that plasma IL-37 is lower in older adults (young: 339 ± 240, middle-aged: 345 ± 234; older: 258 ± 175 pg/mL; P = 0.048), despite elevations in pro-inflammatory markers. As such, the ratios of circulating IL-37 to pro-inflammatory markers were considerably lower in older adults (e.g., IL-37 to C-reactive protein: young, 888 ± 918 vs. older, 337 ± 293; P = 0.02), indicating impaired IL-37 responsiveness to a pro-inflammatory state with aging and consistent with the notion of immunosenescence. These ratios were related to multiple indicators of healthspan, including positively to cardiorespiratory fitness (P < 0.01) and negatively to markers of adiposity, blood pressure, and blood glucose (all P < 0.05). Lastly, we correlated single-nucleotide polymorphisms (SNPs) in the IL37 and ILR8 (the co-receptor for IL-37) genes and found that variants in IL37 SNPs tended to be associated with blood pressure and adiposity (P = 0.08–0.09) but did not explain inter-individual variability in circulating IL-37 concentrations across age (P ≥ 0.23). Overall, our findings provide novel insights into a possible role of IL-37 in biological aging in humans.
- 1 December 2021
- Published by Elsevier in Biophysical Journal
- Vol. 120 (24) , 5657-5673
Single-molecule studies reveal regulatory interactions between master kinases PDK1, AKT1, and PKC
- 1 December 2021
- Published by Elsevier in Biophysical Journal
- Vol. 120 (24) , 5657-5673
Single-molecule studies reveal regulatory interactions between master kinases PDK1, AKT1, and PKC
- Top Cited Papers
- 1 July 2020
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (1) , 101-112
Trimethylamine-N-Oxide Promotes Age-Related Vascular Oxidative Stress and Endothelial Dysfunction in Mice and Healthy Humans
Age-related vascular endothelial dysfunction is a major antecedent to cardiovascular diseases. We investigated whether increased circulating levels of the gut microbiome-generated metabolite trimethylamine-N-oxide induces endothelial dysfunction with aging. In healthy humans, plasma trimethylamine-N-oxide was higher in middle-aged/older (64±7 years) versus young (22±2 years) adults (6.5±0.7 versus 1.6±0.2 µmol/L) and inversely related to brachial artery flow-mediated dilation ( r 2 =0.29, P P G -nitro-L-arginine methyl ester). Acute incubation of carotid arteries with trimethylamine-N-oxide recapitulated these events. Next, treatment with 3,3-dimethyl-1-butanol for 8 to 10 weeks to suppress trimethylamine-N-oxide selectively improved endothelium-dependent dilation in old mice to young levels (peak: 90±2%) by normalizing vascular superoxide production, restoring nitric oxide-mediated dilation, and ameliorating superoxide-related suppression of endothelium-dependent dilation. Lastly, among healthy middle-aged/older adults, higher plasma trimethylamine-N-oxide was associated with greater nitrotyrosine abundance in biopsied endothelial cells, and infusion of the antioxidant ascorbic acid restored flow-mediated dilation to young levels, indicating tonic oxidative stress-related suppression of endothelial function with higher circulating trimethylamine-N-oxide. Using multiple experimental approaches in mice and humans, we demonstrate a clear role of trimethylamine-N-oxide in promoting age-related endothelial dysfunction via oxidative stress, which may have implications for prevention of cardiovascular diseases.
- 1 July 2020
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (1) , 101-112
Top Cited PapersTrimethylamine-N-Oxide Promotes Age-Related Vascular Oxidative Stress and Endothelial Dysfunction in Mice and Healthy Humans
Age-related vascular endothelial dysfunction is a major antecedent to cardiovascular diseases. We investigated whether increased circulating levels of the gut microbiome-generated metabolite trimethylamine-N-oxide induces endothelial dysfunction with aging. In healthy humans, plasma trimethylamine-N-oxide was higher in middle-aged/older (64±7 years) versus young (22±2 years) adults (6.5±0.7 versus 1.6±0.2 µmol/L) and inversely related to brachial artery flow-mediated dilation ( r 2 =0.29, P P G -nitro-L-arginine methyl ester). Acute incubation of carotid arteries with trimethylamine-N-oxide recapitulated these events. Next, treatment with 3,3-dimethyl-1-butanol for 8 to 10 weeks to suppress trimethylamine-N-oxide selectively improved endothelium-dependent dilation in old mice to young levels (peak: 90±2%) by normalizing vascular superoxide production, restoring nitric oxide-mediated dilation, and ameliorating superoxide-related suppression of endothelium-dependent dilation. Lastly, among healthy middle-aged/older adults, higher plasma trimethylamine-N-oxide was associated with greater nitrotyrosine abundance in biopsied endothelial cells, and infusion of the antioxidant ascorbic acid restored flow-mediated dilation to young levels, indicating tonic oxidative stress-related suppression of endothelial function with higher circulating trimethylamine-N-oxide. Using multiple experimental approaches in mice and humans, we demonstrate a clear role of trimethylamine-N-oxide in promoting age-related endothelial dysfunction via oxidative stress, which may have implications for prevention of cardiovascular diseases.
- Open Access
- 18 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Inspiratory Muscle Strength Training Improves Vascular Endothelial Function in Older Adults by Altering Circulating Factors that Suppress Superoxide and Enhance Nitric Oxide
Background: Vascular endothelial dysfunction associated with decreased nitric oxide (NO)‐bioavailability secondary to excessive superoxide‐associated oxidative stress is a key antecedent of age‐associated cardiovascular diseases. High‐resistance inspiratory muscle strength training (IMST) is a promising form of time‐efficient physical training for promoting cardiovascular health with aging. However, the efficacy and mechanisms of IMST for improving endothelial function in older adults have not been established. We hypothesized IMST may induce changes in the molecular composition of the circulating blood that improve endothelial function via superoxide suppression‐related increases in NO bioavailability. Purpose: To determine the efficacy of IMST for improving vascular endothelial function in vivo , the influence of IMST‐induced changes in circulating factors on endothelial superoxide and NO production ex vivo , and IMST‐induced changes in the molecular composition of the circulation. Methods: Twenty older adults underwent 6 weeks of IMST (30 breaths/day; 6 days/week; 75% maximum inspiratory pressure [PI MAX ]) (n=10, 5M/5F, age: 68±2 years) or low‐resistance sham (15% PI MAX ) training (n=10, 6M/4F, age 70±2 years) in a randomized, double‐blind study. Vascular endothelial function was assessed via brachial artery flow‐mediated dilation [FMDBA]. HUVECs were cultured with serum collected at baseline and post‐intervention (n=12; 5 IMST, 7 sham). NO production stimulated with acetylcholine and basal superoxide production from HUVECs were measured using fluorescent microscopy. Plasma metabolite levels were assessed via targeted metabolomics (n=14; 7 IMST, 7 sham) at baseline and post‐intervention with ultra‐high‐performance liquid chromatography‐mass spectrometry. Results: FMDBA increased 45% after 6 weeks of IMST (pre: 4.7±0.8 Δ%, post: 6.8±0.7 Δ%; p=0.01) but not after sham training (pre: 3.7±0.6 Δ%, post: 3.8±0.6 Δ%; p=0.99), such that FMDBA was 79% higher in the IMST group compared to sham training post‐intervention (p=0.01). HUVEC production of NO was 66% higher (p=0.04) while superoxide production was 38% lower post‐intervention in the IMST group vs. sham, though the latter was not statistically significant (p=0.17). Plasma metabolomics revealed greater levels of arginine (p=0.02) and ornithine (p=0.06) in the IMST group vs. sham post‐intervention, consistent with increased NO production. A greater level of dehydroascorbate (p=0.04) and changes in markers of glutathione synthesis (decreased alanine p=0.02; increased cystine p=0.06) were observed in the IMST group vs. sham post‐intervention, suggesting greater antioxidant defense status with IMST. Conclusion: These findings suggest IMST is a promising intervention for improving vascular endothelial function in older adults, in part by inducing changes in the molecular composition of the blood that increases NO bioavailability by suppressing superoxide. Support or Funding Information: AHA 18POST33990034, R21 AG061677
- 18 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Open AccessInspiratory Muscle Strength Training Improves Vascular Endothelial Function in Older Adults by Altering Circulating Factors that Suppress Superoxide and Enhance Nitric Oxide
Background: Vascular endothelial dysfunction associated with decreased nitric oxide (NO)‐bioavailability secondary to excessive superoxide‐associated oxidative stress is a key antecedent of age‐associated cardiovascular diseases. High‐resistance inspiratory muscle strength training (IMST) is a promising form of time‐efficient physical training for promoting cardiovascular health with aging. However, the efficacy and mechanisms of IMST for improving endothelial function in older adults have not been established. We hypothesized IMST may induce changes in the molecular composition of the circulating blood that improve endothelial function via superoxide suppression‐related increases in NO bioavailability. Purpose: To determine the efficacy of IMST for improving vascular endothelial function in vivo , the influence of IMST‐induced changes in circulating factors on endothelial superoxide and NO production ex vivo , and IMST‐induced changes in the molecular composition of the circulation. Methods: Twenty older adults underwent 6 weeks of IMST (30 breaths/day; 6 days/week; 75% maximum inspiratory pressure [PI MAX ]) (n=10, 5M/5F, age: 68±2 years) or low‐resistance sham (15% PI MAX ) training (n=10, 6M/4F, age 70±2 years) in a randomized, double‐blind study. Vascular endothelial function was assessed via brachial artery flow‐mediated dilation [FMDBA]. HUVECs were cultured with serum collected at baseline and post‐intervention (n=12; 5 IMST, 7 sham). NO production stimulated with acetylcholine and basal superoxide production from HUVECs were measured using fluorescent microscopy. Plasma metabolite levels were assessed via targeted metabolomics (n=14; 7 IMST, 7 sham) at baseline and post‐intervention with ultra‐high‐performance liquid chromatography‐mass spectrometry. Results: FMDBA increased 45% after 6 weeks of IMST (pre: 4.7±0.8 Δ%, post: 6.8±0.7 Δ%; p=0.01) but not after sham training (pre: 3.7±0.6 Δ%, post: 3.8±0.6 Δ%; p=0.99), such that FMDBA was 79% higher in the IMST group compared to sham training post‐intervention (p=0.01). HUVEC production of NO was 66% higher (p=0.04) while superoxide production was 38% lower post‐intervention in the IMST group vs. sham, though the latter was not statistically significant (p=0.17). Plasma metabolomics revealed greater levels of arginine (p=0.02) and ornithine (p=0.06) in the IMST group vs. sham post‐intervention, consistent with increased NO production. A greater level of dehydroascorbate (p=0.04) and changes in markers of glutathione synthesis (decreased alanine p=0.02; increased cystine p=0.06) were observed in the IMST group vs. sham post‐intervention, suggesting greater antioxidant defense status with IMST. Conclusion: These findings suggest IMST is a promising intervention for improving vascular endothelial function in older adults, in part by inducing changes in the molecular composition of the blood that increases NO bioavailability by suppressing superoxide. Support or Funding Information: AHA 18POST33990034, R21 AG061677
- 23 January 2020
- Published by Springer Nature in GeroScience
- Vol. 42 (2) , 667-686
Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults
Chronic calorie restriction (CR) improves cardiovascular function and several other physiological markers of healthspan. However, CR is impractical in non-obese older humans due to potential loss of lean mass and bone density, poor adherence, and risk of malnutrition. Time-restricted feeding (TRF), which limits the daily feeding period without requiring a reduction in calorie intake, may be a promising alternative healthspan—extending strategy for midlife and older adults; however, there is limited evidence for its feasibility and efficacy in humans. We conducted a randomized, controlled pilot study to assess the safety, tolerability, and overall feasibility of short-term TRF (eating −1 for 6 weeks) without weight loss in healthy non-obese midlife and older adults, while gaining initial insight into potential efficacy for improving cardiovascular function and other indicators of healthspan. TRF was safe and well-tolerated, associated with excellent adherence and reduced hunger, and did not influence lean mass, bone density, or nutrient intake. Cardiovascular function was not enhanced by short-term TRF in this healthy cohort, but functional (endurance) capacity and glucose tolerance were modestly improved. These results provide a foundation for conducting larger clinical studies of TRF in midlife and older adults, including trials with a longer treatment duration.
- 23 January 2020
- Published by Springer Nature in GeroScience
- Vol. 42 (2) , 667-686
Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults
Chronic calorie restriction (CR) improves cardiovascular function and several other physiological markers of healthspan. However, CR is impractical in non-obese older humans due to potential loss of lean mass and bone density, poor adherence, and risk of malnutrition. Time-restricted feeding (TRF), which limits the daily feeding period without requiring a reduction in calorie intake, may be a promising alternative healthspan—extending strategy for midlife and older adults; however, there is limited evidence for its feasibility and efficacy in humans. We conducted a randomized, controlled pilot study to assess the safety, tolerability, and overall feasibility of short-term TRF (eating −1 for 6 weeks) without weight loss in healthy non-obese midlife and older adults, while gaining initial insight into potential efficacy for improving cardiovascular function and other indicators of healthspan. TRF was safe and well-tolerated, associated with excellent adherence and reduced hunger, and did not influence lean mass, bone density, or nutrient intake. Cardiovascular function was not enhanced by short-term TRF in this healthy cohort, but functional (endurance) capacity and glucose tolerance were modestly improved. These results provide a foundation for conducting larger clinical studies of TRF in midlife and older adults, including trials with a longer treatment duration.
- Open Access
- 21 November 2019
- Published by Wiley in Aging Cell
- Vol. 19 (1) , e13074
Short‐term interleukin‐37 treatment improves vascular endothelial function, endurance exercise capacity, and whole‐body glucose metabolism in old mice
Aging is associated with vascular endothelial dysfunction, reduced exercise tolerance, and impaired whole‐body glucose metabolism. Interleukin‐37 (IL‐37), an anti‐inflammatory cytokine of the interleukin‐1 family, exerts salutary physiological effects in young mice independent of its inflammation‐suppressing properties. Here, we assess the efficacy of IL‐37 treatment for improving physiological function in older age. Old mice (26–28 months) received daily intraperitoneal injections of recombinant human IL‐37 (recIL‐37; 1 µg/200 ml PBS) or vehicle (200 ml PBS) for 10–14 days. Vascular endothelial function (ex vivo carotid artery dilation to increasing doses of acetylcholine, ACh) was enhanced in recIL‐37 vs. vehicle‐treated mice via increased nitric oxide (NO) bioavailability (all p < .05); this effect was accompanied by enhanced ACh‐stimulated NO production and reduced levels of reactive oxygen species in endothelial cells cultured with plasma from IL‐37‐treated animals (p < .05 vs. vehicle plasma). RecIL‐37 treatment increased endurance exercise capacity by 2.4‐fold, which was accompanied by a 2.9‐fold increase in the phosphorylated AMP‐activated kinase (AMPK) to AMPK ratio (i.e., AMPK activation) in quadriceps muscle. RecIL‐37 treatment also improved whole‐body insulin sensitivity and glucose tolerance (p < .05 vs. vehicle). Improvements in physiological function occurred without significant changes in plasma, aortic, and skeletal muscle pro‐inflammatory proteins (under resting conditions), whereas pro‐/anti‐inflammatory IL‐6 was greater in recIL‐37‐treated animals. Plasma metabolomics analysis revealed that recIL‐37 treatment altered metabolites related to pathways involved in NO synthesis (e.g., increased L‐arginine and citrulline/arginine ratio) and fatty acid metabolism (e.g., increased pantothenol and free fatty acids). Our findings provide experimental support for IL‐37 therapy as a novel strategy to improve diverse physiological functions in old age.
- 21 November 2019
- Published by Wiley in Aging Cell
- Vol. 19 (1) , e13074
Open AccessShort‐term interleukin‐37 treatment improves vascular endothelial function, endurance exercise capacity, and whole‐body glucose metabolism in old mice
Aging is associated with vascular endothelial dysfunction, reduced exercise tolerance, and impaired whole‐body glucose metabolism. Interleukin‐37 (IL‐37), an anti‐inflammatory cytokine of the interleukin‐1 family, exerts salutary physiological effects in young mice independent of its inflammation‐suppressing properties. Here, we assess the efficacy of IL‐37 treatment for improving physiological function in older age. Old mice (26–28 months) received daily intraperitoneal injections of recombinant human IL‐37 (recIL‐37; 1 µg/200 ml PBS) or vehicle (200 ml PBS) for 10–14 days. Vascular endothelial function (ex vivo carotid artery dilation to increasing doses of acetylcholine, ACh) was enhanced in recIL‐37 vs. vehicle‐treated mice via increased nitric oxide (NO) bioavailability (all p < .05); this effect was accompanied by enhanced ACh‐stimulated NO production and reduced levels of reactive oxygen species in endothelial cells cultured with plasma from IL‐37‐treated animals (p < .05 vs. vehicle plasma). RecIL‐37 treatment increased endurance exercise capacity by 2.4‐fold, which was accompanied by a 2.9‐fold increase in the phosphorylated AMP‐activated kinase (AMPK) to AMPK ratio (i.e., AMPK activation) in quadriceps muscle. RecIL‐37 treatment also improved whole‐body insulin sensitivity and glucose tolerance (p < .05 vs. vehicle). Improvements in physiological function occurred without significant changes in plasma, aortic, and skeletal muscle pro‐inflammatory proteins (under resting conditions), whereas pro‐/anti‐inflammatory IL‐6 was greater in recIL‐37‐treated animals. Plasma metabolomics analysis revealed that recIL‐37 treatment altered metabolites related to pathways involved in NO synthesis (e.g., increased L‐arginine and citrulline/arginine ratio) and fatty acid metabolism (e.g., increased pantothenol and free fatty acids). Our findings provide experimental support for IL‐37 therapy as a novel strategy to improve diverse physiological functions in old age.
- Open Access
- 1 May 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (5) , e0196678
A PKC-MARCKS-PI3K regulatory module links Ca2+ and PIP3 signals at the leading edge of polarized macrophages
The leukocyte chemosensory pathway detects attractant gradients and directs cell migration to sites of inflammation, infection, tissue damage, and carcinogenesis. Previous studies have revealed that local Ca2+ and PIP3 signals at the leading edge of polarized leukocytes play central roles in positive feedback loop essential to cell polarization and chemotaxis. These prior studies showed that stimulation of the leading edge Ca2+ signal can strongly activate PI3K, thereby triggering a larger PIP3 signal, but did not elucidate the mechanistic link between Ca2+ and PIP3 signaling. A hypothesis explaining this link emerged, postulating that Ca2+-activated PKC displaces the MARCKS protein from plasma membrane PIP2, thereby releasing sequestered PIP2 to serve as the target and substrate lipid of PI3K in PIP3 production. In vitro single molecule studies of the reconstituted pathway on lipid bilayers demonstrated the feasibility of this PKC-MARCKS-PI3K regulatory module linking Ca2+ and PIP3 signals in the reconstituted system. The present study tests the model predictions in live macrophages by quantifying the effects of: (a) two pathway activators—PDGF and ATP that stimulate chemoreceptors and Ca2+ influx, respectively; and (b) three pathway inhibitors—wortmannin, EGTA, and Go6976 that inhibit PI3K, Ca2+ influx, and PKC, respectively; on (c) four leading edge activity sensors—AKT-PH-mRFP, CKAR, MARCKSp-mRFP, and leading edge area that report on PIP3 density, PKC activity, MARCKS membrane binding, and leading edge expansion/contraction, respectively. The results provide additional evidence that PKC and PI3K are both essential elements of the leading edge positive feedback loop, and strongly support the existence of a PKC-MARCKS-PI3K regulatory module linking the leading edge Ca2+ and PIP3 signals. As predicted, activators stimulate leading edge PKC activity, displacement of MARCKS from the leading edge membrane and increased leading edge PIP3 levels, while inhibitors trigger the opposite effects. Comparison of the findings for the ameboid chemotaxis of leukocytes with recently published findings for the mesenchymal chemotaxis of fibroblasts suggests that some features of the emerging leukocyte leading edge core pathway (PLC-DAG-Ca2+-PKC-MARCKS-PIP2-PI3K-PIP3) may well be shared by all chemotaxing eukaryotic cells, while other elements of the leukocyte pathway may be specialized features of these highly optimized, professional gradient-seeking cells. More broadly, the findings suggest a molecular mechanism for the strong links between phospho-MARCKS and many human cancers.
- 1 May 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (5) , e0196678
Open AccessA PKC-MARCKS-PI3K regulatory module links Ca2+ and PIP3 signals at the leading edge of polarized macrophages
The leukocyte chemosensory pathway detects attractant gradients and directs cell migration to sites of inflammation, infection, tissue damage, and carcinogenesis. Previous studies have revealed that local Ca2+ and PIP3 signals at the leading edge of polarized leukocytes play central roles in positive feedback loop essential to cell polarization and chemotaxis. These prior studies showed that stimulation of the leading edge Ca2+ signal can strongly activate PI3K, thereby triggering a larger PIP3 signal, but did not elucidate the mechanistic link between Ca2+ and PIP3 signaling. A hypothesis explaining this link emerged, postulating that Ca2+-activated PKC displaces the MARCKS protein from plasma membrane PIP2, thereby releasing sequestered PIP2 to serve as the target and substrate lipid of PI3K in PIP3 production. In vitro single molecule studies of the reconstituted pathway on lipid bilayers demonstrated the feasibility of this PKC-MARCKS-PI3K regulatory module linking Ca2+ and PIP3 signals in the reconstituted system. The present study tests the model predictions in live macrophages by quantifying the effects of: (a) two pathway activators—PDGF and ATP that stimulate chemoreceptors and Ca2+ influx, respectively; and (b) three pathway inhibitors—wortmannin, EGTA, and Go6976 that inhibit PI3K, Ca2+ influx, and PKC, respectively; on (c) four leading edge activity sensors—AKT-PH-mRFP, CKAR, MARCKSp-mRFP, and leading edge area that report on PIP3 density, PKC activity, MARCKS membrane binding, and leading edge expansion/contraction, respectively. The results provide additional evidence that PKC and PI3K are both essential elements of the leading edge positive feedback loop, and strongly support the existence of a PKC-MARCKS-PI3K regulatory module linking the leading edge Ca2+ and PIP3 signals. As predicted, activators stimulate leading edge PKC activity, displacement of MARCKS from the leading edge membrane and increased leading edge PIP3 levels, while inhibitors trigger the opposite effects. Comparison of the findings for the ameboid chemotaxis of leukocytes with recently published findings for the mesenchymal chemotaxis of fibroblasts suggests that some features of the emerging leukocyte leading edge core pathway (PLC-DAG-Ca2+-PKC-MARCKS-PIP2-PI3K-PIP3) may well be shared by all chemotaxing eukaryotic cells, while other elements of the leukocyte pathway may be specialized features of these highly optimized, professional gradient-seeking cells. More broadly, the findings suggest a molecular mechanism for the strong links between phospho-MARCKS and many human cancers.
- Open Access
- 1 December 2017
- Published by Elsevier in Biophysical Journal
- Vol. 113 (11) , 2396-2405
Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP3 Signaling
- 1 December 2017
- Published by Elsevier in Biophysical Journal
- Vol. 113 (11) , 2396-2405
Open AccessSingle-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP3 Signaling
- Open Access
- 24 October 2016
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 55 (46) , 6395-6405
Regulation of a Coupled MARCKS–PI3K Lipid Kinase Circuit by Calmodulin: Single-Molecule Analysis of a Membrane-Bound Signaling Module
Amoeboid cells that employ chemotaxis to travel up an attractant gradient possess a signaling network assembled on the leading edge of the plasma membrane that senses the gradient and remodels the actin mesh and cell membrane to drive movement in the appropriate direction. In leukocytes such as macrophages and neutrophils, and perhaps in other amoeboid cells as well, the leading edge network includes a positive feedback loop in which the signaling of multiple pathway components is cooperatively coupled. Cytoplasmic Ca2+ is a recently recognized component of the feedback loop at the leading edge where it stimulates phosphoinositide-3-kinase (PI3K) and the production of its product signaling lipid phosphatidylinositol 3,4,5-trisphosphate (PIP3). A previous study implicated Ca2+-activated protein kinase C (PKC) and the phosphatidylinositol 4,5-bisphosphate (PIP2) binding protein MARCKS as two important players in this signaling, because PKC phosphorylation of MARCKS releases free PIP2 that serves as the membrane binding target and substrate for PI3K. This study asks whether calmodulin (CaM), which is known to directly bind MARCKS, also stimulates PIP3 production by releasing free PIP2. Single-molecule fluorescence microscopy is used to quantify the surface density and enzyme activity of key protein components of the hypothesized Ca2+–CaM–MARCKS–PIP2–PI3K–PIP3 circuit. The findings show that CaM does stimulate PI3K lipid kinase activity by binding MARCKS and displacing it from PIP2 headgroups, thereby releasing free PIP2 that recruits active PI3K to the membrane and serves as the substrate for the generation of PIP3. The resulting CaM-triggered activation of PI3K is complete in seconds and is much faster than PKC-triggered activation, which takes minutes. Overall, the available evidence implicates both PKC and CaM in the coupling of Ca2+ and PIP3 signals and suggests these two different pathways have slow and fast activation kinetics, respectively.
- 24 October 2016
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 55 (46) , 6395-6405
Open AccessRegulation of a Coupled MARCKS–PI3K Lipid Kinase Circuit by Calmodulin: Single-Molecule Analysis of a Membrane-Bound Signaling Module
Amoeboid cells that employ chemotaxis to travel up an attractant gradient possess a signaling network assembled on the leading edge of the plasma membrane that senses the gradient and remodels the actin mesh and cell membrane to drive movement in the appropriate direction. In leukocytes such as macrophages and neutrophils, and perhaps in other amoeboid cells as well, the leading edge network includes a positive feedback loop in which the signaling of multiple pathway components is cooperatively coupled. Cytoplasmic Ca2+ is a recently recognized component of the feedback loop at the leading edge where it stimulates phosphoinositide-3-kinase (PI3K) and the production of its product signaling lipid phosphatidylinositol 3,4,5-trisphosphate (PIP3). A previous study implicated Ca2+-activated protein kinase C (PKC) and the phosphatidylinositol 4,5-bisphosphate (PIP2) binding protein MARCKS as two important players in this signaling, because PKC phosphorylation of MARCKS releases free PIP2 that serves as the membrane binding target and substrate for PI3K. This study asks whether calmodulin (CaM), which is known to directly bind MARCKS, also stimulates PIP3 production by releasing free PIP2. Single-molecule fluorescence microscopy is used to quantify the surface density and enzyme activity of key protein components of the hypothesized Ca2+–CaM–MARCKS–PIP2–PI3K–PIP3 circuit. The findings show that CaM does stimulate PI3K lipid kinase activity by binding MARCKS and displacing it from PIP2 headgroups, thereby releasing free PIP2 that recruits active PI3K to the membrane and serves as the substrate for the generation of PIP3. The resulting CaM-triggered activation of PI3K is complete in seconds and is much faster than PKC-triggered activation, which takes minutes. Overall, the available evidence implicates both PKC and CaM in the coupling of Ca2+ and PIP3 signals and suggests these two different pathways have slow and fast activation kinetics, respectively.
- Open Access
- 1 April 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (8) , 1811-1825
Regulation of PI3K by PKC and MARCKS: Single-Molecule Analysis of a Reconstituted Signaling Pathway
- 1 April 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (8) , 1811-1825
Open AccessRegulation of PI3K by PKC and MARCKS: Single-Molecule Analysis of a Reconstituted Signaling Pathway